Open Access
Issue
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 1029 - 1033
Section Les anticorps dans les maladies autres qu’oncologiques
DOI https://doi.org/10.1051/medsci/2019204
Published online 06 January 2020
  1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011 ; 365: 2205–2219. [Google Scholar]
  2. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994 ; 344: 1105–1110. [CrossRef] [PubMed] [Google Scholar]
  3. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 2017 ; 389: 2328–2337. [CrossRef] [PubMed] [Google Scholar]
  4. Stohl W.. Future prospects in biologic therapy for systemic lupus erythematosus. Nat Rev Rheumatol 2013 ; 9: 705–720. [CrossRef] [PubMed] [Google Scholar]
  5. Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 2015 ; 27: 127–133. [CrossRef] [PubMed] [Google Scholar]
  6. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006 ; 6: 394–403. [Google Scholar]
  7. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998 ; 41: 1552–1563. [CrossRef] [PubMed] [Google Scholar]
  8. Nam JL, Takase-Minegishi K, Ramiro S, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2017 ; 76: 1113–1136. [CrossRef] [PubMed] [Google Scholar]
  9. Braun J, Kiltz U, Heldmann F, Baraliakos X. Emerging drugs for the treatment of axial and peripheral spondyloarthritis. Exp Opin Emerg Drugs 2015 ; 20: 1–14. [CrossRef] [Google Scholar]
  10. Otten MH, Anink J, Spronk S, van Suijlekom-Smit LW. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Ann Rheum Dis 2013 ; 72: 1806–1812. [CrossRef] [PubMed] [Google Scholar]
  11. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010: CD008331. [PubMed] [Google Scholar]
  12. Scott LJ. Sarilumab: first global approval. Drugs 2017 ; 77: 705–712. [CrossRef] [PubMed] [Google Scholar]
  13. Stone JH, Klearman M, Collinson N. Trial of Tocilizumab in giant-cell arteritis. N Engl J Med 2017 ; 377: 1494–1495. [Google Scholar]
  14. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010 ; 363: 221–232. [Google Scholar]
  15. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?. Ann Rheum Dis 2018 ; 77: 175–187. [CrossRef] [PubMed] [Google Scholar]
  16. Van den Bosch F, Deodhar A. Treatment of spondyloarthritis beyond TNF-alpha blockade. Best Practice Res Clin Rheumatol 2014 ; 28: 819–827. [CrossRef] [Google Scholar]
  17. Kunwar S, Dahal K, Sharma S. Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatol Int 2016 ; 36: 1065–1075. [CrossRef] [PubMed] [Google Scholar]
  18. Sieper J, Poddubnyy D. New evidence on the management of spondyloarthritis. Nat Rev Rheumato 2016 ; 12: 282–295. [CrossRef] [Google Scholar]
  19. Baeten D, Ostergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis 2018 ; 77: 1295–1302. [CrossRef] [PubMed] [Google Scholar]
  20. Poddubnyy D, Hermann KG, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 2014 ; 73: 817–823. [CrossRef] [PubMed] [Google Scholar]
  21. EULAR therapeutic drug monitoring study group. https://wwweularorg/clinical_affairs_study_groupscfm [Google Scholar]
  22. Mulleman D, Balsa A. Adalimumab concentration-based tapering strategy: as good as the recommended dosage. Ann Rheum Dis 2018 ; 77: 473–475. [CrossRef] [PubMed] [Google Scholar]
  23. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002 ; 46: 1451–1459. [CrossRef] [PubMed] [Google Scholar]
  24. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007 ; 66: 921–926. [CrossRef] [PubMed] [Google Scholar]
  25. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006 ; 54: 3782–3789. [CrossRef] [PubMed] [Google Scholar]
  26. Ducourau E, Mulleman D, Paintaud G, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011 ; 13: R105. [Google Scholar]
  27. Bejan-Angoulvant T, Ternant D, Daoued F, et al. Brief report: relationship between serum infliximab concentrations and risk of infections in patients treated for spondyloarthritis. Arthritis Rheumatol 2017 ; 69: 108–113. [CrossRef] [PubMed] [Google Scholar]
  28. Jani M, Dixon WG, Lunt M, et al. The association of biologic drug-levels with infection risk: results from the british society for rheumatology biologics register for rheumatoid arthritis. EULAR annual meeting. Ann Rheum Dis 2018: A163. [Google Scholar]
  29. Krieckaert CL, Nair SC, Nurmohamed MT, et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis 2015 ; 74: 361–368. [CrossRef] [PubMed] [Google Scholar]
  30. L’Ami MJ, Krieckaert CL, Nurmohamed MT, et al. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis 2018 ; 77: 484–487. [CrossRef] [PubMed] [Google Scholar]
  31. Ducourau E, Ternant D, Lequerre T, et al. Towards an individualised target concentration of adalimumab in rheumatoid arthritis. Ann Rheum Dis 2014 ; 73: 1428–1429. [CrossRef] [PubMed] [Google Scholar]
  32. Monitoring of monoclonal antibodies group in Europe (MAGE) for inflammatory diseases. www.lestudium-iascom/content/monitoring-monoclonal-antibodies-group-europe-mage-inflammatory-diseases [Google Scholar]
  33. Dreesen E, Bossuyt P, Mulleman D, et al. Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Clin Pharmacol 2017 ; 9: 1–11. [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.